Home > Research > Publications & Outputs > Cyclin-dependent kinase 12, a novel drug target...

Research

Associated organisational units

Electronic data

  • MainText-AAM

    Rights statement: The Author's Accepted Manuscript (the accepted version of the manuscript as submitted by the author) may only be posted 6 months after the paper is published, consistent with our self-archiving embargo. Please note that the Author’s Accepted Manuscript may not be released under a Creative Commons license. For Nature Research Terms of Reuse of archived manuscripts please see: http://www.nature.com/authors/policies/license.html#terms

    Accepted author manuscript, 6.26 MB, PDF document

    Available under license: None

Links

Text available via DOI:

View graph of relations

Cyclin-dependent kinase 12, a novel drug target for visceral leishmaniasis

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

Cyclin-dependent kinase 12, a novel drug target for visceral leishmaniasis. / Wyllie, Susan; Thomas, Michael; Patterson, Stephen et al.
In: Nature, Vol. 560, 25.07.2018, p. 192-197.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Wyllie, S, Thomas, M, Patterson, S, Crouch, S, De Rycker, M, Lowe, R, Gresham, S, Urbaniak, MD, Otto, TD, Stojanovski, L, Simeons, FRC, Manthri, S, MacLean, LM, Zuccotto, F, Homeyer, N, Pflaumer, H, Boesche, M, Sastry, L, Connolly, P, Albrecht, S, Berriman, M, Drewes, G, Gray, DW, Ghidelli-Disse, S, Dixon, S, Fiandor, JM, Wyatt, PG, Ferguson, MAJ, Fairlamb, AH, Miles, TJ, Read, KD & Gilbert, IH 2018, 'Cyclin-dependent kinase 12, a novel drug target for visceral leishmaniasis', Nature, vol. 560, pp. 192-197. https://doi.org/10.1038/s41586-018-0356-z

APA

Wyllie, S., Thomas, M., Patterson, S., Crouch, S., De Rycker, M., Lowe, R., Gresham, S., Urbaniak, M. D., Otto, T. D., Stojanovski, L., Simeons, F. R. C., Manthri, S., MacLean, L. M., Zuccotto, F., Homeyer, N., Pflaumer, H., Boesche, M., Sastry, L., Connolly, P., ... Gilbert, I. H. (2018). Cyclin-dependent kinase 12, a novel drug target for visceral leishmaniasis. Nature, 560, 192-197. https://doi.org/10.1038/s41586-018-0356-z

Vancouver

Wyllie S, Thomas M, Patterson S, Crouch S, De Rycker M, Lowe R et al. Cyclin-dependent kinase 12, a novel drug target for visceral leishmaniasis. Nature. 2018 Jul 25;560:192-197. doi: 10.1038/s41586-018-0356-z

Author

Wyllie, Susan ; Thomas, Michael ; Patterson, Stephen et al. / Cyclin-dependent kinase 12, a novel drug target for visceral leishmaniasis. In: Nature. 2018 ; Vol. 560. pp. 192-197.

Bibtex

@article{00e9f9cc35ac491daf31fd3611dd6047,
title = "Cyclin-dependent kinase 12, a novel drug target for visceral leishmaniasis",
abstract = "Visceral leishmaniasis causes considerable mortality and morbidity in many parts of the world. There is an urgent need for the development of new, effective treatments for this disease. Here we describe the development of an anti-leishmanial drug-like chemical series based on a pyrazolopyrimidine scaffold. The leading compound from this series (7, DDD853651/GSK3186899) is efficacious in a mouse model of visceral leishmaniasis, has suitable physicochemical, pharmacokinetic and toxicological properties for further development, and has been declared a preclinical candidate. Detailed mode-of-action studies indicate that compounds from this series act principally by inhibiting the parasite cdc-2-related kinase 12 (CRK12), thus defining a druggable target for visceral leishmaniasis.",
author = "Susan Wyllie and Michael Thomas and Stephen Patterson and Sabrinia Crouch and {De Rycker}, Manu and Rhiannon Lowe and Stephanie Gresham and Urbaniak, {Michael Daniel} and Otto, {Thomas D.} and Laste Stojanovski and Simeons, {Frederick R. C.} and Sujatha Manthri and MacLean, {Lorna M.} and Fabio Zuccotto and Nadine Homeyer and Hannah Pflaumer and Markus Boesche and Lalitha Sastry and Paul Connolly and Sebastian Albrecht and Matt Berriman and Gerard Drewes and Gray, {David W.} and Sonja Ghidelli-Disse and Susan Dixon and Fiandor, {Jose M.} and Wyatt, {Paul G.} and Ferguson, {Michael A. J.} and Fairlamb, {Alan H.} and Miles, {Timothy J.} and Read, {Kevin D.} and Gilbert, {Ian H.}",
year = "2018",
month = jul,
day = "25",
doi = "10.1038/s41586-018-0356-z",
language = "English",
volume = "560",
pages = "192--197",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",

}

RIS

TY - JOUR

T1 - Cyclin-dependent kinase 12, a novel drug target for visceral leishmaniasis

AU - Wyllie, Susan

AU - Thomas, Michael

AU - Patterson, Stephen

AU - Crouch, Sabrinia

AU - De Rycker, Manu

AU - Lowe, Rhiannon

AU - Gresham, Stephanie

AU - Urbaniak, Michael Daniel

AU - Otto, Thomas D.

AU - Stojanovski, Laste

AU - Simeons, Frederick R. C.

AU - Manthri, Sujatha

AU - MacLean, Lorna M.

AU - Zuccotto, Fabio

AU - Homeyer, Nadine

AU - Pflaumer, Hannah

AU - Boesche, Markus

AU - Sastry, Lalitha

AU - Connolly, Paul

AU - Albrecht, Sebastian

AU - Berriman, Matt

AU - Drewes, Gerard

AU - Gray, David W.

AU - Ghidelli-Disse, Sonja

AU - Dixon, Susan

AU - Fiandor, Jose M.

AU - Wyatt, Paul G.

AU - Ferguson, Michael A. J.

AU - Fairlamb, Alan H.

AU - Miles, Timothy J.

AU - Read, Kevin D.

AU - Gilbert, Ian H.

PY - 2018/7/25

Y1 - 2018/7/25

N2 - Visceral leishmaniasis causes considerable mortality and morbidity in many parts of the world. There is an urgent need for the development of new, effective treatments for this disease. Here we describe the development of an anti-leishmanial drug-like chemical series based on a pyrazolopyrimidine scaffold. The leading compound from this series (7, DDD853651/GSK3186899) is efficacious in a mouse model of visceral leishmaniasis, has suitable physicochemical, pharmacokinetic and toxicological properties for further development, and has been declared a preclinical candidate. Detailed mode-of-action studies indicate that compounds from this series act principally by inhibiting the parasite cdc-2-related kinase 12 (CRK12), thus defining a druggable target for visceral leishmaniasis.

AB - Visceral leishmaniasis causes considerable mortality and morbidity in many parts of the world. There is an urgent need for the development of new, effective treatments for this disease. Here we describe the development of an anti-leishmanial drug-like chemical series based on a pyrazolopyrimidine scaffold. The leading compound from this series (7, DDD853651/GSK3186899) is efficacious in a mouse model of visceral leishmaniasis, has suitable physicochemical, pharmacokinetic and toxicological properties for further development, and has been declared a preclinical candidate. Detailed mode-of-action studies indicate that compounds from this series act principally by inhibiting the parasite cdc-2-related kinase 12 (CRK12), thus defining a druggable target for visceral leishmaniasis.

U2 - 10.1038/s41586-018-0356-z

DO - 10.1038/s41586-018-0356-z

M3 - Journal article

VL - 560

SP - 192

EP - 197

JO - Nature

JF - Nature

SN - 0028-0836

ER -